5 completed, 1 not yet recruiting, 1 withdrawn. 7 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 7 | Completed 5, Not yet recruiting 1, Withdrawn 1 |
Follow Eye Manifestations: new trials by email Literature Review of Eye Manifestations trials Research Report on Eye Manifestations
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Acoltremon Ophthalmic Solution 0.003% on Tear Production and Symptoms in Patients With Tear Deficiency and Concurrent Neuropathic Corneal Pain acoltremon ophthalmic solution 0.003% - Ocular Pain, Dry Eye | Phase 4 | Not yet recruiting | University of South Florida | 28 | 2026-10-01 | 2026-10-06 |
| Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate 1% Oph Susp, Prolensa 0.07% Ophthalmic Solution - Corneal Edema, Corneal Defect | Phase 4 | Completed | Nicole Fram M.D. | 50 | 2023-06-01 | 2026-02-20 |
| Cool vs Room-temperature Artificial Tears Refresh Plus Preservative-free Lubricant Eye Drops - Diabetic Retinopathy With Macular Edema of Both Eyes (Diagnosis), Central Retinal Vein Occlusion With Macular Edema | Phase 4 | Completed | University of Iowa | 124 | 2022-03-01 | 2025-03-04 |
| The Effect of Upneeq (Oxymetazoline Hydrochloride 0.1%) on Eyelid Position, Eye Redness, and Eye Appearance Oxymetazoline hydrochloride 0.1% ophthalmic solution, Placebo - Ptosis, Eyelid, Conjunctiva Inflamed | Phase 4 | Completed | University of Miami | 114 | 2021-06-08 | 2023-04-24 |
| Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Corneal Transplant Surgery Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate 1% Oph Susp - Corneal Edema, Corneal Defect | Phase 4 | Completed | Nicole Fram M.D. | 36 | 2020-10-16 | 2023-07-24 |
| Effect of Intracameral Dexamethasone After Phacoemulsification in Diabetics on Corneal Endothelial Cell Density Dexamethasone, Saline Solutions, Intraocular - Diabetes Mellitus, Corneal Endothelial Cell Loss | Phase 4 | Withdrawn | Cairo University | 2018-01-01 | 2019-07-24 | |
| Efficacy and Safety of PRO-155 on Inflammation of the Conjunctival Surface in Subjects With Grade I-III Pterygium vs Placebo. PRO-155, Placebo - Pterygium, Ocular Pain | Phase 4 | Completed | Laboratorios Sophia S.A de C.V. | 166 | 2017-12-13 | 2019-11-20 |
Eye Pain (5) · Corneal Edema (2) · Macular Edema (2) · Blepharoptosis (1) · Conjunctivitis (1) · Corneal Endothelial Cell Loss (1) · Diabetes Mellitus (1) · Disease (1) · Dry Eye Syndromes (1) · Pterygium (1)
Eye Diseases (7) · Pathological Conditions, Signs and Symptoms (7) · Signs and Symptoms (7) · Neurologic Manifestations (5) · Pain (5) · Corneal Diseases (3) · Conjunctival Diseases (2) · Macular Degeneration (2) · Pathologic Processes (2) · Retinal Degeneration (2) · Retinal Diseases (2) · Endocrine System Diseases (1) · Eyelid Diseases (1) · Glucose Metabolism Disorders (1)
Calcium Dobesilate (3) · Dexamethasone (2) · Ophthalmic Solutions (2) · bromfenac (2) · prednisolone acetate (2) · Methylprednisolone (1) · Oxymetazoline (1) · Sodium Chloride (1)
Nicole Fram M.D. (2) · Cairo University (1) · Laboratorios Sophia S.A de C.V. (1) · University of Iowa (1) · University of Miami (1) · University of South Florida (1)
United States (5) · Mexico (1)
Ahmed A Abdel Azim, MD (1) · Ahmed A. Dahab, MD (1) · Ayman GA Elnahry, Msc (1) · Douglas Jin, MD (1) · Nicole Fram, MD (1) · Nicole R Fram, M.D. (1) · Pedram Hamrah, MD (1) · Shaimaa A Arfeen, MD (1) · Wendy W. Lee, MD (1)